🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer

RecruitingNAAges 20 Years - anyFemaleYong Wha Moon
NCT07651124 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer. Participants undergo the following process: There must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject. These are processed into human cells for administration and injected into the subject.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Recurrent ovarian cancer * There is a cancerous lesion that can be removed by biopsy or surgery. Exclusion Criteria: * Patient with immunodeficiency or autoimmune diseases that may be exacerbated by immunotherapy * Patient deemed unsuitable by the principal investigator
💊

What it tests

  • autologous tumor-infiltrating lymphocytes
📍

Where

1 site
Bundang CHA Medical Center
Gyeonggi-do, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy